VCI Wealth Management LLC Takes Position in Edwards Lifesciences Co. (NYSE:EW)

VCI Wealth Management LLC bought a new stake in shares of Edwards Lifesciences Co. (NYSE:EW) during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm bought 11,534 shares of the medical research company’s stock, valued at approximately $879,000.

Other institutional investors and hedge funds also recently made changes to their positions in the company. Stevens Capital Management LP grew its holdings in Edwards Lifesciences by 18.1% in the 4th quarter. Stevens Capital Management LP now owns 15,090 shares of the medical research company’s stock worth $1,151,000 after acquiring an additional 2,311 shares during the last quarter. Pittenger & Anderson Inc. bought a new stake in Edwards Lifesciences in the 4th quarter worth $520,000. Magnolia Capital Advisors LLC bought a new stake in Edwards Lifesciences in the 4th quarter worth $511,000. South Dakota Investment Council grew its holdings in Edwards Lifesciences by 15.2% in the 4th quarter. South Dakota Investment Council now owns 257,600 shares of the medical research company’s stock worth $19,642,000 after acquiring an additional 33,896 shares during the last quarter. Finally, GAMMA Investing LLC bought a new stake in Edwards Lifesciences in the 4th quarter worth $180,000. Institutional investors own 79.46% of the company’s stock.

Edwards Lifesciences Stock Down 0.7 %

Edwards Lifesciences stock traded down $0.60 during trading hours on Thursday, hitting $88.01. The stock had a trading volume of 4,166,251 shares, compared to its average volume of 3,829,875. The company has a quick ratio of 2.40, a current ratio of 3.38 and a debt-to-equity ratio of 0.09. The stock has a market capitalization of $52.98 billion, a P/E ratio of 38.53, a price-to-earnings-growth ratio of 4.35 and a beta of 1.05. Edwards Lifesciences Co. has a 12-month low of $60.57 and a 12-month high of $96.12. The stock’s 50-day moving average price is $90.23 and its 200-day moving average price is $78.69.

Edwards Lifesciences (NYSE:EW) last issued its earnings results on Tuesday, February 6th. The medical research company reported $0.64 earnings per share (EPS) for the quarter, hitting the consensus estimate of $0.64. The business had revenue of $1.53 billion during the quarter, compared to analysts’ expectations of $1.50 billion. Edwards Lifesciences had a net margin of 23.35% and a return on equity of 23.56%. The business’s revenue for the quarter was up 13.3% compared to the same quarter last year. During the same period in the previous year, the company earned $0.64 earnings per share. Equities research analysts anticipate that Edwards Lifesciences Co. will post 2.76 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of brokerages have issued reports on EW. Oppenheimer raised their price target on shares of Edwards Lifesciences from $93.00 to $100.00 and gave the stock an “outperform” rating in a report on Monday, March 18th. Bank of America raised shares of Edwards Lifesciences from a “neutral” rating to a “buy” rating in a research note on Thursday, March 7th. Mizuho lifted their target price on shares of Edwards Lifesciences from $95.00 to $105.00 and gave the company a “buy” rating in a research note on Thursday, April 11th. Evercore ISI lifted their target price on shares of Edwards Lifesciences from $86.00 to $92.00 and gave the company an “in-line” rating in a research note on Thursday, April 4th. Finally, Wells Fargo & Company raised shares of Edwards Lifesciences from an “equal weight” rating to an “overweight” rating and set a $94.00 target price on the stock in a research note on Friday, February 2nd. One equities research analyst has rated the stock with a sell rating, seven have given a hold rating and ten have assigned a buy rating to the company’s stock. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $91.73.

Insider Transactions at Edwards Lifesciences

In other news, VP Catherine M. Szyman sold 27,000 shares of Edwards Lifesciences stock in a transaction that occurred on Thursday, February 15th. The shares were sold at an average price of $85.62, for a total value of $2,311,740.00. Following the completion of the sale, the vice president now directly owns 34,814 shares in the company, valued at $2,980,774.68. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. In related news, VP Catherine M. Szyman sold 27,000 shares of the business’s stock in a transaction that occurred on Thursday, February 15th. The shares were sold at an average price of $85.62, for a total transaction of $2,311,740.00. Following the completion of the sale, the vice president now directly owns 34,814 shares in the company, valued at $2,980,774.68. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, VP Jean-Luc M. Lemercier sold 14,400 shares of the business’s stock in a transaction that occurred on Monday, April 8th. The shares were sold at an average price of $92.32, for a total transaction of $1,329,408.00. Following the sale, the vice president now owns 173,849 shares of the company’s stock, valued at $16,049,739.68. The disclosure for this sale can be found here. Insiders sold 194,004 shares of company stock worth $17,166,254 over the last three months. 1.29% of the stock is currently owned by company insiders.

About Edwards Lifesciences

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.